Skip to Main Content
Contribute Try STAT+ Today

Cell and gene therapy companies are opening the door to a paradigm shift in medicine as they rapidly develop effective new therapies and change patients’ lives for the better. They are also carving out a unique path in life sciences leadership.

As a result of their rapid growth, cell and gene therapy (C&GT) companies face a distinct set of challenges — from manufacturing and pricing to supply chain transportation and product security — that sets them apart from the rest of the biopharma sector. They’re subject to the pressures of delivering complex innovations in very short time frames, putting company leaders under high pressure from day one. That means management teams must be built faster and be more broadly based than in purely R&D-focused drug discovery enterprises.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.